Concr secures Innovate UK funding to advance cancer precision therapy

Our portfolio company, Concr,  has been awarded a prestigious grant from Innovate UK, which will play a pivotal role in advancing the efforts to enable precision medicine.

Concr uses Bayesian computational frameworks adopted from astrophysics to interlink disparate and messy oncology data, allowing scientists to confidently identify and develop biomarkers of drug response, with minimal data requirements. These sophisticated biomarker predictions de-risk pivotal clinical trials and improve patient outcomes through effective stratification.

Innovate UK is renowned for its commitment to supporting UK enterprises that develop innovative solutions to critical issues. Its Advancing Precision Medicine competition funds industry-led collaborative R&D innovation projects to develop digital and data-enabled tools, as well as multi-modal approaches for more accurate diagnosis and treatment stratification.

We are deeply grateful to Innovate UK for recognising the importance of our work and providing us with this invaluable grant. This funding will empower us to make meaningful strides in clinical validation of Concr technology and demonstrate how this technology can improve treatment decision-making process for cancer patients. It will also help the pharmaceutical industry to better select people for clinical studies, selecting those who are most likely to benefit from their cancer drugs. We are excited to embark on this journey and eager to create a brighter future for our community.

said Dr Uzma Asghar, Concr’s Chief Scientific Officer and AI-VISION Project Manager.

Access to their full press release here